ELVN

Over the past six months, Enliven Therapeutics' stock (ELVN) experienced significant volatility, increasing by 127.21% from September 2025 to September 2026 and gaining 92.5% over the past 12 months, but also decreasing by 28.7% in the month leading up to October 9, 2026. Key events included positive initial Phase 1b data for ELVN-001 in CML in March 2026 and FDA alignment on the ENABLE-2 Phase 3 trial design for ELVN-001 in October 2026, which paradoxically led to a 'sell the news' reaction. The company reported its second-quarter financial results on August 5, 2026, with an earnings per share (EPS) of -$0.49, missing analyst estimates. Insider selling by company directors and officers in September and October 2026 also contributed to stock volatility. Additionally, Rick Fair became CEO in December 2025, which was associated with increased stock-based compensation expenses in the fourth quarter of 2025.